• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Personalis, Inc. - Common Stock (NQ:PSNL)

11.25 +1.60 (+16.58%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Personalis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™
January 12, 2026
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights
January 08, 2026
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors
December 17, 2025
From Personalis, Inc.
Via Business Wire
News headline image
New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer
December 11, 2025
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Participate in the Piper Sandler 37th Annual Healthcare Conference
November 18, 2025
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast Cancer
November 10, 2025
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Reports Third Quarter 2025 Financial Results
November 04, 2025
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Announce Third Quarter 2025 Financial Results
October 21, 2025
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing
October 16, 2025
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 15, 2025
From Personalis, Inc.
Via Business Wire
News headline image
CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test
September 10, 2025
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing
September 03, 2025
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Participate in Upcoming Investor Conferences
August 27, 2025
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Reports Second Quarter 2025 Financial Results
August 05, 2025
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Announce Second Quarter 2025 Financial Results
July 22, 2025
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 18, 2025
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients
July 09, 2025
From Personalis, Inc.
Via Business Wire
News headline image
Personalis’ NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO
June 03, 2025
From Personalis, Inc.
Via Business Wire
News headline image
New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse
June 02, 2025
From Personalis, Inc.
Via Business Wire
News headline image
Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection
May 22, 2025
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Participate at the Craig-Hallum 22nd Annual Investor Conference
May 14, 2025
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Reports First Quarter 2025 Financial Results
May 06, 2025
From Personalis, Inc.
Via Business Wire
News headline image
Personalis’ NeXT Personal® Detects 100% of Colorectal Cancer Relapses Ahead of Imaging in VICTORI Cancer Study
April 28, 2025
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Announce First Quarter 2025 Financial Results
April 22, 2025
From Personalis, Inc.
Via Business Wire
News headline image
Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection
April 22, 2025
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Participate at the 24th Annual Needham Virtual Healthcare Conference
March 26, 2025
From Personalis, Inc.
Via Business Wire
News headline image
New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection
March 03, 2025
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Reports Fourth Quarter and Full Year 2024 Financial Results
February 27, 2025
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Participate at the TD Cowen's 45th Annual Health Care Conference
February 18, 2025
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Announce Fourth Quarter and Full Year 2024 Financial Results
February 13, 2025
From Personalis, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap